Pancreatic Cancer Breakthrough: Johns Hopkins Targets KLF5 Gene for Precision Treatment

Researchers at Johns Hopkins Medicine have identified a gene, KLF5, that appears to play a critical role in the spread of pancreatic cancer, offering a potential new target for treatment. The findings, published in Molecular Cancer, suggest that epigenetic changes – alterations in gene expression rather than changes to the DNA code itself – are key drivers of metastasis in this aggressive disease.

Pancreatic cancer is notoriously difficult to treat, largely because This proves often diagnosed at an advanced stage when it has already spread to other parts of the body. Understanding the mechanisms that allow pancreatic cancer cells to metastasize is therefore crucial for developing more effective therapies.

The study focused on lab-grown pancreatic cancer cells. Using genetic techniques, the researchers systematically deactivated various genes to observe their impact on cancer cell growth and spread. KLF5 consistently emerged as a major player in promoting the growth and dissemination of these aggressive, spreading cancer cells. Further analysis of tissue samples from 13 pancreatic cancer patients revealed that 10 of them exhibited elevated KLF5 activity in at least one metastatic tumor, reinforcing the gene’s potential role in disease progression.

KLF5 doesn’t act alone. The research team discovered that it regulates the activity of two other genes, NCAPD2 and MTHFD1. These genes were highly active in metastatic pancreatic cancer cells but were relatively inactive in the primary tumor cells. This suggests that KLF5 orchestrates a shift in gene expression that facilitates the spread of the cancer.

Importantly, the study highlights the role of epigenetics in this process. KLF5 appears to influence the chemical modifications of DNA, effectively turning genes “on” or “off” without altering the underlying genetic code. This epigenetic reprogramming allows cancer cells to adapt and thrive in new environments, contributing to metastasis.

The researchers found that even subtle changes in KLF5 expression levels can significantly impact the growth and spread of pancreatic cancer cells. This is encouraging because it suggests that therapies aimed at modulating KLF5 activity don’t necessarily need to completely shut down the gene to be effective. Several compounds targeting KLF5 are currently under development, offering hope for new treatment options.

The research also sheds light on the complex interplay between different signaling pathways within cancer cells. The authors discovered that KLF5 interacts with proteins called RUVBL1 and RUVBL2, which are involved in regulating gene expression. These interactions are crucial for KLF5’s ability to drive lineage plasticity – the ability of cancer cells to switch between different states, contributing to tumor heterogeneity and resistance to treatment.

Specifically, the study found that RUVBL1 and RUVBL2 help KLF5 bind to specific regions of the DNA called enhancers, which control the activity of other genes. By blocking the activity of RUVBL1 and RUVBL2, researchers were able to suppress KLF5-dependent transcription and inhibit the growth of pancreatic cancer cells in laboratory settings.

This discovery opens up a new avenue for therapeutic intervention. Small-molecule inhibitors targeting RUVBL1/2 ATPase activity have shown promising anti-cancer effects in preclinical studies, suggesting that they could be used to disrupt the KLF5 signaling pathway and slow down the progression of pancreatic cancer.

The findings build on previous research demonstrating the importance of KLF5 in other cancers, including liver cancer. A study published in September 2024 showed that elevated choline levels drive KLF5-dominated transcriptional reprogramming to facilitate liver cancer progression. This reinforces the idea that KLF5 is a master regulator of cancer cell behavior across different tissues.

While these findings are promising, it’s important to note that this research was conducted using lab-grown cells. Further studies are needed to confirm these results in animal models and, in human clinical trials. However, the identification of KLF5 and its associated pathways represents a significant step forward in our understanding of pancreatic cancer metastasis and provides a valuable new target for the development of more effective treatments.